XML 27 R11.htm IDEA: XBRL DOCUMENT v3.22.0.1
Revenue Recognition and Concentration of Credit Risk
 12 Months Ended
Dec. 31, 2021
Revenue from Contract with Customer [Abstract]  
Revenue Recognition and Concentration of Credit Risk Revenue Recognition and Concentration of Credit RiskDuring the years ended December 31, 2021, 2020 and 2019, the Company recognized revenue from various license and other agreements. The following table indicates the percentage of total revenues in excess of 10% with any single customer:
Customer2021 Revenue% of Total
Revenue		2020 Revenue% of Total
Revenue		2019 Revenue% of Total
Revenue
AstraZeneca$41,659 2 %$170,587 2 %$3,194,877 78 %
Advaccine— — 5,000,000 68 — — 
Plumbline Life Sciences, Inc. (affiliated entity)245,310 14 1,370,396 18 — — 
Department of Defense754,853 43 — — — — 
All other, including affiliated entities732,936 41 870,237 12 917,053 22 
Total revenue$1,774,758 100 %1$7,411,220 100 %$4,111,930 100 %

Of the total revenue recognized during the year ended December 31, 2021, $46,000 was in deferred revenue as of December 31, 2020. During the year ended December 31, 2020, the Company recognized revenue of $127,000 that was included in deferred revenue at December 31, 2019. Performance obligations are generally satisfied within 12 months of the initial contract date.
As of December 31, 2021, $3.6 million, or 65%, and $1.9 million, or 34%, of the Company's accounts receivable was attributable to the DoD and the CEPI MERS grant, respectively. As of December 31, 2020, $11.4 million, or 62%, and $7.1 million, or 38%, of the Company's accounts receivable was attributable to the DoD and Advaccine, respectively. There is minimal credit risk with these customers based upon collection history, their size and financial condition. Accordingly, the Company does not consider it necessary to record a reserve for uncollectible accounts receivable.